Home » Halozyme Gets FDA Orphan Drug Status for PEGPH20 to Treat Pancreatic Cancer
Halozyme Gets FDA Orphan Drug Status for PEGPH20 to Treat Pancreatic Cancer
U.S.-based biopharmaceutical firm Halozyme Therapeutics has received orphan drug designation from the FDA for its PEGylated recombinant human hyaluronidase (PEGPH20) to treat pancreatic cancer.
Pharmaceutical Business Review
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May